Partnership agreement signed on 22 November to broaden distribution and promotion of cough and cold brands such as Shidagong, Gelite and Ruike in China&n...
Bracco, a global leader in diagnostic imaging, and ulrich GmbH & Co. KG, a renowned German medical device manufacturer specializing in contrast media i...
TBI is an urgent and prominent public health challenge, impacting millions each year as a result of head trauma from accidents, falls, sports-related incid...
Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TMdrug delive...
Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, and NYU Langone Health, the nation’s top-ranked academic medical cen...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with Uli...
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients Drug discovery research coll...
“We’re seeing increased demand for Parse’s Evercode single cell sequencing solutions across Asia, and we believe our products are poised ...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral s...
Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...
Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatm...
© 2025 Biopharma Boardroom. All Rights Reserved.
